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EducationLacosamide (LCM) is a novel antiepileptic drug (AED) approved by the FDA for adjunctive treatment of partial
epilepsy with and without secondary generalization. Lacosamide dose-dependent dysrhythmias (PR-interval
prolongation, AV block, and atrial ﬁbrillation/ﬂutter) have been reported. This case represents the ﬁrst instance
of LCM-induced atrial ﬁbrillation following a low loading dose (200 mg). Risk factors for atrial ﬁbrillation are
addressed and discussed in the context of this case. Full cardiac history is recommended prior to patients
being initiated on LCM. Cardiac monitoring may be required for at-risk patients on LCM. Clinicians need to be
cognizant of this potential adverse effect.
© 2012 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.1. Introduction
Lacosamide (LCM) is a novel antiepileptic drug (AED) approved by
the U.S. Food and Drug Administration (FDA) for the adjunct treat-
ment of partial epilepsy with and without secondary generalization
[1]. Lacosamide selectively modulates voltage-gated sodium channels
by enhancing slow inactivation without affecting fast inactivation to
exert its antiepileptic activity [1–3]. Lacosamide has linear pharmaco-
kinetics, reaches maximum concentration within 1–4 h following oral
administration, and has a half-life of 13 h [2]. Lacosamide is a potent
antiepileptic agent with superior efﬁcacy compared to placebo in
patients with partial seizures [4,5]. The choice of AED is related to
both its efﬁcacy in treating seizures and its side-effect proﬁle.
Dose-dependent LCM-induced cardiac dysrhythmias have been
reported in recent literature [4,6–9]. High-dose LCM (600 mg total
daily dose) has been associated with atrial ﬁbrillation/ﬂutter. TheEpileptology, London, United
Neurology and Anesthesiology,
rson Street, Suite #2200, New
fman@verizon.net
nc. Open access under CC BY-NC-SA licauthors report a case believed to represent the ﬁrst instance of
low-dose LCM-induced atrial ﬁbrillation.
2. Method
Case analysis was done with PubMed literature review.
3. Case report
A 67-year-old right-handed woman with history of epilepsy,
migraines, and recently diagnosed plasma cell multiple myeloma
with lambda-free light chains and with swollen tongue presented
to our institution for autologous bone marrow transplant. There was
no known history of structural heart disease or conduction abnormal-
ities though a family history (mother/brother) of atrial ﬁbrillation
was later determined. One week following the bone marrow trans-
plant, frequent episodes of staring associated with oral and facial
automatisms (lip smacking and head shaking) were noted which
prompted neurology consultation.
Medications at time of consultation included primidone 250 mg
daily, ﬂuconazole 400 mg daily, acyclovir 400 mg every 12 h, ﬁlgrastim
300 μg daily, methyl-prednisolone 40 mg IV daily, pantoprazole 40 mg
daily, potassium chloride, and clotrimazole mouthwash 10 mg ﬁve
times a daywhich she did not receive that day due to epigastric discom-
fort. The patient had received loperamide 10 mg 3 times in the last
2 days and ondansetron 8 mg IV on the day prior to consultation.ense.
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normal on the day of consultation excluding sodium 134 mEq/L, fasting
glucose 108 mg/dL, hemoglobin 8.5 g/dL, and hematocrit 24.5%. Pheno-
barbital level was 3.6 μg/mL. Her ECG revealed a sinus rhythm at
96 bpm with premature ventricular contractions with QTc of 437 ms
and PR of 156 ms.
During this consultation, the patient revealed a history of three
generalized tonic-clonic (GTC) seizures at age 21 associated with an
aura described as tinnitus. The convulsive seizure activity responded
to primidone 250 mg total daily dose; however, the patient reported
ongoing tinnitus occurring once monthly and had been told by her
family that she would have brief periods of behavioral arrest with
staring, which she minimized by stating that she was thinking of a
response.
Initial routine EEG revealed 1) disorganized background character-
ized by diffuse slowing with frontally predominant theta and delta
activities and intermittent semi-rhythmic delta activity; 2) intermittent
left fronto-temporal polymorphic delta activity; and 3) few left fronto-
temporal high-amplitude sharp waves (Fig. 1). Clinical presentation
and EEGwere consistent with partial epilepsywith left temporal region
complex partial seizures.
Following initial evaluation by the neurology team, levetiracetam
250 mg IV twice daily was initiated without signiﬁcant change in
clinical status. Intravenous administration was required as the patient
was not tolerating oral medications and had vomited her primidone.
Her episodes increased in frequency with descriptive features
including continuous tinnitus, staring, facial automatisms, limited
verbal responses and lethargy. Levetiracetam was titrated to 500 mg
IV twice daily with primidone 300 mg daily, and the patient was
placed on continuous video-EEG (vEEG) to better characterize seizure
activity and to monitor treatment response. During a four-hour
period on continuous vEEG, greater than 30 episodes were recorded
with electrographic correlation including seizures with and without
secondary generalization (Fig. 2). The patient had continued lethargy
with altered mental status between episodes consistent with complex
partial status epilepticus. Immediate treatment with lorazepam 2 mg
IV bolus was ineffective. Levetiracetam was increased to 1000 mg
twice daily, and the patient received a loading dose of lacosamide
200 mg IV given over 60 min.Fig. 1. Initial roThe patient was noted to have an irregular cardiac rhythm on the
vEEG telemetry lead at the end of the lacosamide infusion (Fig. 3). A
12-lead ECG conﬁrmed atrial ﬁbrillation with rapid ventricular response
(132 bpm). Cardiac telemetry was initiated and continued until the pa-
tient was discharged. Cardiology was consulted for this new-onset atrial
ﬁbrillation. At time of cardiac consultation, the patient's comprehensive
metabolic panel and complete blood count were normal excluding sodi-
um 128 mEq/L, potassium 3.4 mEq/L, glucose 142 mg/dL, phosphorus
2.1 mg/dL, white blood cell count 0.1 thousand/μL, red blood cell count
2.4 million/μL, hemoglobin 7.3 g/dL, hematocrit 21%, and platelet count
45 thousand/μL. Pertinent normal laboratories included troponin
Ib0.03 ng/mL, magnesium 1.8 mg/dL, and TSH 1.56 mIU/L. Lacosamide
was discontinued following the infusion and the atrial ﬁbrillation,
which did not respond tometoprolol 2.5 mg IV, spontaneously resolved
within 8 h. A trans-thoracic echocardiogram (TTE) was performed
on the following day and revealed a normal left ventricular size and sys-
tolic function with an estimated ejection fraction of 55%, a normal right
ventricular size and systolic function, normal bi-atrial size, mild aortic
insufﬁciency, and mild tricuspid regurgitation with moderate pulmo-
nary hypertension (right ventricular systolic pressure of 59 mm Hg).
A subsequent TTE conﬁrmed these ﬁndings. Cardiology concluded that
the atrial ﬁbrillation was induced by the lacosamide infusion as there
were no structural or motion abnormalities.
Anticonvulsant regimen was changed to levetiracetam 1500 mg IV
twice daily and, following two boluses of phenobarbital 600 mg IV,
phenobarbital 60 mg IV every 8 h without signiﬁcant change in seizure
frequency. Video-EEG showed a seizure frequency of 6 to 8 events per
hour, each lasting approximately 60 s in duration, consisting of left
temporal rhythmic sharp waves with staring. The patient received phe-
nytoin 1200 mg IV loading dose following which the vEEG recorded a
three-hour seizure-free period without epileptiform activity; thereafter,
the patient remained seizure-free though intermittent sharp waves
were noted. Levetiracetam was discontinued, and seizure freedom
persisted with phenobarbital 60 mg IV every eight hours and phenytoin
100 mg IV every eight hours with respective anticonvulsant blood levels
of 23.9 μg/mL and 2.1 μg/mL (free).
Ninety-six hours after the initial atrial ﬁbrillation, the patient had
another brief period of atrial ﬁbrillation that lasted several minutes
without any clinical complication. A full 48 h without seizure activityutine EEG.
Fig. 2. Seizure activity with sinus rhythm pre-lacosamide infusion.
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cardiac telemetry during the remaining two weeks of her admission
during which time there were no further episodes of atrial ﬁbrillation.
Upon discharge, the patient returned to her primary care neurologist.4. Discussion
This unique case of apparent low-dose lacosamide-induced atrial
ﬁbrillation in a patient with refractory epilepsy and nonconvulsive
complex partial status epilepticus allows the discussion of several
key points both speciﬁc to this patient and to the LCM treatment of
patients considered to be at high risk for cardiac dysrhythmias.
First, patients often minimize their symptoms in acute and chronic
medical conditions as well as adverse drug reactions which may
lead to increased morbidity and mortality [10–12]. In this instance,
minimizing symptoms led to untreated complex partial seizures; for
though her tonic-clonic seizures were controlled with primidone,
the patient had ongoing periods of tinnitus with behavioral arrest
and staring. Minimizing these epileptic symptoms led to an unneces-
sary treatment gap.Fig. 3. Atrial ﬁbrillation posSecond, several adverse cardiac events have been reported with
LCM. Events include dose-dependent PR-interval prolongation, ﬁrst-,
second- and third-degree AV blocks, and atrial ﬁbrillation/atrial
ﬂutter with high-dose LCM (600 mg/day) [4,6–9,13,14].
Third, current clinical practice and recent literature suggest that LCM
may be used in older and critically ill patients [15–17]. This patient popu-
lation is at greater risk for atrial ﬁbrillation as the reported risk factors for
atrial ﬁbrillation include, but are not limited to, older age, male gender,
hypertension, diabetes, congestive heart failure, myocardial infarction,
cardiac surgery, valvular disease, severe sepsis, hyperthyroidism, obesity,
and smoking [18–21]. Older age was a risk factor in this case.
Fourth, cardiac amyloidosis is a risk factor for atrial ﬁbrillation [22].
The patient had a swollen tongue at admission and post hospitalization
laboratories conﬁrmed amyloid. These ﬁndings are consistent with pre-
sumptive amyloidosis. Though the echocardiogramwas normal, a cardi-
ac biopsy was not performed, and as such, early cardiac amyloidosis
could not be excluded. Therefore, cardiac amyloidosis may have been a
risk factor in this case.
Fifth, analysis of the Framingham Offspring Study noted that
parental atrial ﬁbrillation is associated with a 1.85 odds ratio for atrial
ﬁbrillation in the offspring [23]. In this case, both the patient's mothert-lacosamide infusion.
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factor in this case [19].
Sixth, the patient's second period of atrial ﬁbrillation, lasting
several minutes 96 h after the LCM-associated atrial ﬁbrillation, may
imply unknown cardiac pathology as a predisposing risk factor.
Seventh, atrial ﬁbrillation occurred at the end of the LCM IV
infusion, consistent with the theoretical maximum blood concentra-
tion [14]. Lacosamide has linear (ﬁrst-order) pharmacokinetics with
an elimination half-life of 13 h [2,24]. The spontaneous resolution of
atrial ﬁbrillation within 8 h following the LCM infusion suggests a
concentration-dependent effect.
Eighth, the patient had multiple potential risk factors (older age,
possible cardiac amyloidosis, genetic predisposition, and possible
unknown cardiac pathology) for cardiac arrhythmias. In the context
of additive risk factors, the probability of LCM inducing the initial
episode of atrial ﬁbrillation was determined by the Naranjo's Adverse
Reaction Probability Scale as probable (scored as 5) [25].
Ninth, as LCM may cause (or precipitate) cardiac dysrhythmias in-
cluding atrial ﬁbrillation in susceptible patients, recommendations
prior to the initiation of LCM may include 1) obtaining baseline 12-lead
ECG, 2) obtaining careful cardiac history verifying potential risk factors
including family history of atrial ﬁbrillation or other dysrhythmias, 3)
obtaining comprehensive metabolic panel with magnesium, 4) normal-
izing electrolyte levels, and 5) adjusting LCMdose based on renal and he-
patic functions. Further, as this paper suggests that LCM-induced atrial
ﬁbrillationmay occur at low doses cardiacmonitoring during both initial
LCM administration and titration should be considered.
There are speciﬁc limitations to this paper. As a case report (N=1),
the ﬁndings cannot be generalized. In this case, and other studies of
atrial ﬁbrillation, pre-existing asymptomatic atrial ﬁbrillation cannot
be excluded. Lacosamide blood level was not measured. Cardiac
biopsy to conﬁrm amyloidosis impacting the heart was not obtained.
Though the patient had a family history of atrial ﬁbrillation, no genetic
assessment was performed to conﬁrm familial atrial ﬁbrillation. The
patient was lost to clinical follow-up. Finally, the patient could not be
re-challenged with lacosamide for ethical reasons.5. Conclusion
Low-dose lacosamide may induce atrial ﬁbrillation, especially in
patients at risk for cardiac arrhythmias. Clinicians need to be aware
of this potential adverse drug effect and to evaluate and monitor
at-risk patients appropriately. Further research is indicated to conﬁrm
this ﬁnding.Acknowledgments
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